Navlimetostat
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Navlimetostat, covering 2026-04-22 to 2026-06-03. Get the full timeline:
Most recent: Clinical Trial Update: A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) [Phase 2, Phase 3]